2022 American Transplant Congress
CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation
Department of Pathology, Johns Hopkins University, Baltimore, MD
*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…2022 American Transplant Congress
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
Columbia University Medical Center, New York, NY
*Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…2022 American Transplant Congress
p40 Homodimers Stimulate Graft Dendritic Cells to Produce IL-15 Driving Endogenous Donor-Reactive Memory CD8 T Cell Activation within High-Risk Cardiac Allografts
*Purpose: Acute allograft injury occurring during the first 1-2 days post-transplant is mediated by graft infiltrating endogenous donor-reactive memory CD8 T cells and requires their…2022 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…2022 American Transplant Congress
Outcomes After Conversion to Belatacept in Pediatric Kidney Transplantation
Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France
*Purpose: Belatacept (CTLA-Ig) is a selective co-stimulation blocker that is associated with reduced dnDSA, improved renal function, and prolonged allograft survival in adult transplant recipients…2022 American Transplant Congress
Perioperative IL-6 Blockade Promotes Intra-Graft Regulation and Prevents Costimulation-Blockade Resistant Rejection
*Purpose: Our group has recently shown that CTLA4-Ig monotherapy leads to limited murine heart allograft survival associated with decreased Treg frequencies and early acute T-cell…2022 American Transplant Congress
Predictors of Response to Belatacept Conversion in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
1Virginia Commonwealth University, Richmond, VA, 2University of Alberta, Edmonton AB, AB, Canada
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of kidney transplant (KT) loss. Current therapies have unclear efficacy and side effects. We…2022 American Transplant Congress
T and B Cell Response to 3 Dose Covid Vaccine Series for Kidney Transplant Patients on Belatacept
*Purpose: Data shows COVID vaccine response after 2 doses in patients on Belatacept immunosuppression (IS) is low, with reported rates of seroconversion (as measured by…2022 American Transplant Congress
Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates
MGH Center for Transplantation Sciences, Boston, MA
*Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been…2022 American Transplant Congress
TNX-1500, an Fc-Modified Anti-cd154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival
*Purpose: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to replace current clinical immunosuppression. TNX-1500 (TNX) is a novel humanized anti-CD154…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 30
- Next Page »